Mariner’s Ocular Therapeutix OCUL Stock Holding History

Mariner’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$514K	Buy	52,339 +39,557	+309%	+$359K	﹤0.01%	2438
2026 Q1	$108K	Buy	+12,782	New	+$122K	﹤0.01%	3313

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mariner's OCUL Position: Q2 2026 in Review

Mariner increased its Ocular Therapeutix (OCUL) stake by 309% in Q2 2026, buying an estimated $359K and bringing the position to 52,339 shares worth $514K. The position accounts for ﹤0.01% of the portfolio, ranked #2438.

Mariner first reported a position in OCUL in Q1 2026 and has held it in 2 quarters since. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Mariner held 52,339 shares of Ocular Therapeutix worth $514K as of Q2 2026.
Mariner bought 39,557 Ocular Therapeutix shares in Q2 2026, an estimated $359K.
Ocular Therapeutix made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2438 holding.
Mariner first reported a position in Ocular Therapeutix in Q1 2026 and has held it in 2 quarters since.
263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.